Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Cancelled)

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Previously Presented) The dosage form of claim 26, wherein the insoluble film forming polymer is selected from the group consisting of cellulose acetate, ethylcellulose, poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) in a 1:2:0.1 weight ratio, and mixtures thereof.

14. (Previously Presented) The dosage form of claim 26, wherein the enteric polymer is selected from the group consisting of hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, polyvinylacetate phthalate, polymethacrylate-based polymers, and copolymers and mixtures thereof.

15. (Previously Presented) The dosage form of claim 14, wherein the enteric polymer is selected from a poly(methacrylic acid, methyl methacrylate) in a weight ratio of 1:2 and/or poly(methacrylic acid, methyl methacrylate) in a weight ratio of 1:1.

16. (Previously Presented) The dosage form of claim14, wherein the insoluble film forming polymer is selected from the group consisting of cellulose acetate, ethylcellulose, poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) in a 1:2:0.1 weight ratio, and mixtures thereof.

17. (Cancelled)

18. (Previously Presented) The dosage form of claim16, wherein the enteric polymer is selected from a poly(methacrylic acid, methyl methacrylate) in a weight ratio of 1:2 and/or poly(methacrylic acid, methyl methacrylate) in a weight ratio of 1:1.

19. (Previously Presented) The dosage form of claim 26 wherein the coated particles in said second portion are comprised of, based upon the total dry weight of the coated particles in the second portion, from about 10 percent to about 40 percent of the controlled release composition.

20. (Previously Presented) The dosage form of claim18 wherein the coated particles in said second portion are comprised of, based upon the total dry weight of the coated particles in the second portion, from about 10 percent to about 40 percent of the controlled release composition.

21. (Previously Presented) The dosage form of claim 26, wherein the NSAID is a propionic acid derivative NSAID.

22. (Previously Presented) The dosage form of claim18, wherein the NSAID is a propionic acid derivative NSAID.

23. (Cancelled)

24. (Cancelled)

25. (Cancelled)

26. (Previously Presented) A liquid suspension dosage form comprising:

a) a first portion of particles containing an NSAID, said NSAID being released from the dosage form in a substantially immediate manner upon contact of the dosage form with a dissolution medium;

b) a second portion of particles containing said NSAID, said NSAID being released from the particles in a controlled manner upon contact of the dosage form with the dissolution medium; and

c) water, or mixtures of water and a pharmaceutically acceptable water-miscible co-solvent selected from the group consisting of glycols, alcohols, and glycerol,

wherein said particles in said second portion are comprised of a core that is substantially covered by a coating thereon, and said coating is comprised of a controlled release composition comprising one or more enteric polymers and one or more insoluble film forming polymers wherein the weight ratio of the insoluble film forming polymer(s) and the enteric polymer(s) is from about 80:20 to about 99:1, said first portion of particles and said second portion of particles are suspended in component c), wherein the pKa of said NSAID is greater than the pH of the liquid suspension pharmaceutical dosage form, and wherein the dosage form has a duration of therapeutic effect for at least about 12 hours after administration.

27. (Previously Presented) The liquid suspension dosage form of claim 26 comprising, based upon the total weight of the liquid suspension dosage form:

a) from about 0.25 percent to about 30 percent of a first portion containing an NSAID, said NSAID being released from the dosage form in a substantially immediate manner upon contact of the dosage form with a dissolution medium;

b) from about 0.0125 percent to about 0.025 percent of a second portion of particles containing said NSAID, said NSAID being released from the dosage form in a controlled manner upon contact of the dosage form with the dissolution medium; and

c) from about 20 percent to about 70 percent of water, or mixtures of water and a pharmaceutically acceptable water-miscible co-solvent selected from the group consisting of glycols, alcohols, and glycerol,

wherein the dosage form has a duration of therapeutic effect for at least about 12 hours after administration.

28. (Cancelled)

29. (Previously Presented) A method for treating pain in a mammal in need thereof, which comprises administering the dosage form of claim 27 in an amount effective for providing pain relief to the mammal for a period of at least about 12 hours after administration of the dosage form.

30. (Original) A method for treating pain in a mammal in need thereof, which comprises administering the dosage form of claim 26 in an amount effective for providing pain relief to the mammal for a period of at least about 12 hours after administration of the dosage form.

31. (Previously Presented) A method of administering an NSAID in a pharmaceutical liquid suspension dosage form to a mammal in need thereof, said method comprises providing to a mammal said dosage form such that the mammal receives an immediate release dose of said NSAID at the beginning of said 12 hour time period, and a controlled release dose of said NSAID over a period of about 12 hours after administration of said dosage form, wherein no further NSAID is provided during said 12 hour time period, wherein said dosage form comprises particles comprised of a core that is substantially covered by a coating thereon, and said coating is comprised of a controlled release

composition comprising an enteric polymer and an insoluble film forming polymer wherein the weight ratio of the insoluble film forming polymer and the enteric polymer is from about 80:20 to about 99:1 and wherein the pKa of said NSAID is greater than the pH of the liquid suspension pharmaceutical dosage form.

32. (Cancelled)

33. (Cancelled)

34. (Cancelled)

35. (Cancelled)

36. (Previously Presented) The dosage form of claim 27, wherein the insoluble film forming polymer is selected from the group consisting of cellulose acetate, ethylcellulose, poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) in a 1:2:0.1 weight ratio, and mixtures thereof.

37. (Previously Presented) The dosage form of claim 27, wherein the enteric polymer is selected from the group consisting of hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, polyvinylacetate phthalate, polymethacrylate-based polymers, and copolymers and mixtures thereof.

38. (Previously Presented) The dosage form of claim 27, wherein the enteric polymer is selected from a poly(methacrylic acid, methyl methacrylate) in a weight ratio of 1:2 and/or poly(methacrylic acid, methyl methacrylate) in a weight ratio of 1:1.

39. (Previously Presented) The dosage form of claim 36, wherein the enteric polymer is selected from the group consisting of hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate,

polyvinylacetate phthalate, polymethacrylate-based polymers, and copolymers and mixtures thereof.

40. (Previously Presented) The dosage form of claim 36, wherein the enteric polymer is selected from a poly(methacrylic acid, methyl methacrylate) in a weight ratio of 1:2 and/or poly(methacrylic acid, methyl methacrylate) in a weight ratio of 1:1.

41. (Previously Presented) The dosage form of claim 27 wherein the coated particles in said second portion are comprised of, based upon the total dry weight of the coated particles in the second portion, from about 10 percent to about 40 percent of the controlled release composition.

42. (Previously Presented) The dosage form of claim 40 wherein the coated particles in said second portion are comprised of, based upon the total dry weight of the coated particles in the second portion, from about 10 percent to about 40 percent of the controlled release composition.

43. (Cancelled)

44. (Cancelled)

45. (Cancelled)

46. (Cancelled)

47. (Previously Presented) The dosage form of claim 18, wherein said NSAID is ibuprofen.

48. (Previously Presented) The dosage form of claim 26, wherein said NSAID is ibuprofen.

49. (Previously Presented) The dosage form of claim 29, wherein said NSAID is ibuprofen.

50. (Previously Presented) The dosage form of claim 30, wherein said NSAID is ibuprofen.

51. (Previously Presented) The dosage form of claim 31, wherein said NSAID is ibuprofen.

52. (Previously Presented) The dosage form of claim 40, wherein said NSAID is ibuprofen.